Recently Featured

ASGCT President Terry Flotte Touts Rare Disease Initiatives as His Term Ends

May 28, 2026
As his term as President of the American Society of Gene and Cell Therapy (ASGCT) concludes, Dr. Terry Flotte emphasizes the critical focus on rare and ultra-rare diseases. Flotte, who is also Editor in Chief of Human Gene Therapy, highlights the upcoming conference in Boston as a pivotal moment for advancing access to cell and…

FDA Projects Significant Novel Drug Approvals for 2025

May 28, 2026
The FDA has announced a robust pipeline for novel drug approvals in 2025, signaling a potential increase in innovative therapies entering the market. This projection comes as the agency continues to prioritize expedited review processes for drugs that address unmet medical needs, particularly in areas such as oncology, rare diseases, and chronic conditions. This anticipated…

Viral Vector Production Processes: Addressing Manufacturing Bottlenecks for Advanced Therapies

May 27, 2026
Viral vectors are pivotal in the delivery of advanced therapies, facilitating gene transfer for the treatment of inherited disorders, cancer, and other severe diseases. However, the manufacturing of these vectors remains a significant bottleneck, primarily due to high costs, scalability challenges, and process variability. As the viral vector landscape evolves, there is a pronounced shift…

Secondary Packaging Emerges as Key Player in Smart Tech Adoption and Sustainability Efforts

May 27, 2026
Secondary packaging is gaining recognition as a pivotal element in advancing smart technologies and achieving sustainability goals within the pharmaceutical industry. Historically overshadowed by primary packaging, secondary packaging is now being acknowledged for its potential to support companies in meeting their environmental objectives. As organizations set both short- and long-term sustainability targets, secondary packaging is…

Ongoing Cases